ClinicalTrials.gg
CompletedNCT01294241Updated Jan 23, 2018Results posted

Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)

A Phase 2 interventional study of Oleogel-S10 and Mepilex® soft silicone faced polyurethane foam dressing in Inherited Epidermolysis Bullosa, sponsored by Birken AG. Completed at 1 site in Germany. Open to participants aged 1 Year to 95 Years. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Birken AG (part of Chiesi Farmaceutici S.p.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
1 Year to 95 Years
Sex
All
01

Study summary

The purpose of this study was to compare intra-individually the reepithelialization of skin lesion(s) in inherited Epidermolysis bullosa (either 1 wound ≥10 cm2 and ≤200 cm2 in size divided in 2 equal halves or 2 comparable wounds of ≥5 cm2 each) treated with Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only.

Read the detailed description

This study was designed as an open-label, prospective, controlled, blindly evaluated, monocentric phase II case series documentation in patients with inherited Epidermolysis bullosa (EB). The investigator either identified 1 EB wound ≥10 cm2 and ≤200 cm2 in size and divided it into 2 halves or selected 2 comparable wounds of ≥5 cm2 each. One (half of the) EB wound was treated with Oleogel-S10 and non-adhesive wound dressing. The other wound (half) was covered with a non-adhesive wound dressing only (Mepilex®) as control. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'. This was an open-label study. The investigator, the participant, and the sponsor knew the identity of the treatment. Two independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound (half) that were taken before start of treatment, during wound dressing changes and at the end of treatment on Day 14/Day 28.

02

Conditions studied

  • Inherited Epidermolysis Bullosa

Browse trials for

Keywords

  • Epidermolysis bullosa
  • Wound healing
  • Epithelialization
03

In context

Epidermolysis Bullosa

86 studies on the registry are indexed under Epidermolysis Bullosa; 17 are open to participants now.

This study's enrollment of 10 is below the median of 14 across 67 interventional studies indexed under Epidermolysis Bullosa.

Browse Epidermolysis Bullosa studies →

Lead sponsor

Birken AG is the lead sponsor of 6 studies on the registry; none are open to participants now.

First submitted before Birken AG became part of Chiesi Farmaceutici S.p.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 1-95 years
  2. Patient and/or his/her legal representative was informed, read and understood the patient information/ form and gave written informed consent
  3. Patients with inherited EB with at least 1 skin lesion between 10 cm2 and 200 cm2 (alternatively 2 comparable lesions of at least 5 cm2 each)
  4. Patient and/or his/her legal representative was able and willing to follow study procedures and instructions including the following:

    1. Application of Oleogel-S10 on (1 half of) the wound at every wound dressing change
    2. Regular visits during the treatment period (14 days in 'recent wounds' to 28 days in 'chronic wounds')
  5. Negative pregnancy test in women of within 7 days before start of treatment
  6. Women of childbearing potential agreed to use an effective method of (Pearl Index \< 1, e.g. hormonal contraception including the combined oral contraceptive pill, the transdermal patch, and the contraceptive vaginal ring, intrauterine devices or sterilization) during treatment and for at least 6 months thereafter
  7. Men of procreative capacity agreed to use an effective method of contraception during treatment and for at least 6 months thereafter

Exclusion criteria

Exclusion Criteria:

  1. Systemic treatment with during the last 30 days
  2. Uncontrolled diabetes mellitus or diabetic ulcers
  3. Diseases or conditions that could, in the opinion of the investigator, interfere with the assessment of safety, tolerance or efficacy
  4. Skin disorders adversely affecting wound healing or involving the areas eligible for study treatment
  5. to the trial medication or surgical dressings to be used
  6. Multiple allergic disorders
  7. Administration of drugs within 3 months before screening
  8. Investigations or changes in management for an existing medical condition
  9. Low probability to complete the study per protocol for whatever reason
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Oleogel-S10

    The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

    Drug: Oleogel-S10 · Device: Mepilex® soft silicone faced polyurethane foam dressing

  • Other
    Non-adhesive wound dressing

    Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

    Device: Mepilex® soft silicone faced polyurethane foam dressing

Interventions

  • DrugOleogel-S10

    Drug pages: Episalvan · Birch triterpenes

    1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

    Also known as: Sericare®

  • DeviceMepilex® soft silicone faced polyurethane foam dressing

    Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

    Also known as: Cutaneous patch

06

What researchers measure

Primary outcomes

  1. Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds'

    The primary end point was the progress of reepithelialization from baseline to either Day 14 ('recent wounds') or Day 28 ('chronic wounds') of the EB wound (half) treated with Oleogel-S10 and non-adhesive wound dressing (Mepilex®) intra-individually compared to the other wound (half) covered with non-adhesive wound dressing only (intra-individual comparison). Two independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound (half) that were taken before start of treatment, during wound dressing changes and at the end of treatment on Day 14/Day 28. They evaluated each series and decided whether 1 wound (half) reepithelialized faster than the other ('winner'), or whether there was no difference in reepithelialization.

    Time frame: 14 days for 'recent wounds', 28 days for 'chronic wounds'

Secondary outcomes

  1. Percentage of Wound Epithelialization at Day 7±1

    The secondary endpoint was the intra-individual difference in median percentage of wound epithelialization at Day 7±1. Sizes of wound areas were measured using a digital wound evaluation program from the EB Center at the Department of Dermatology, University Medical Center Freiburg.

    Time frame: Day 7±1

  2. Percentage of Wound Epithelialization at Day 14±1

    The secondary endpoint was the intra-individual difference in median percentage of wound epithelialization at Day 14±1. Sizes of wound areas were measured using a digital wound evaluation program from the EB Center at the Department of Dermatology, University Medical Center Freiburg.

    Time frame: Day 14±1

07

Results

Posted Jan 23, 2018
Limitations and caveats
Small sample size, subjects with dystrophic Epidermolysis bullosa only, difficult wound size analysis at fixed study days due to several episodes of re-trauma in both intervention and control wounds

Participant flow

Participants were enrolled from 03 Nov 2010 to 14 Jun 2011 at 1 center (University Medical Center Freiburg) in 1 country (Germany).

Participant flow — Overall Study
MilestoneAll Study Participants
Started10
Completed10
Not completed0

Outcome measures

PrimaryIntra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds'

The primary end point was the progress of reepithelialization from baseline to either Day 14 ('recent wounds') or Day 28 ('chronic wounds') of the EB wound (half) treated with Oleogel-S10 and non-adhesive wound dressing (Mepilex®) intra-individually compared to the other wound (half) covered with non-adhesive wound dressing only (intra-individual comparison). Two independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound (half) that were taken before start of treatment, during wound dressing changes and at the end of treatment on Day 14/Day 28. They evaluated each series and decided whether 1 wound (half) reepithelialized faster than the other ('winner'), or whether there was no difference in reepithelialization.

Time frame:
14 days for 'recent wounds', 28 days for 'chronic wounds'
Reported as:
Count of units · Wounds
Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds'
WoundsAll Study Participants
Faster healing of wound treated with Oleogel-S108
Faster healing of wound treated with dressing0
Statistical analysis
  • All Study Participants · Two-sided exact binomial test · p = =0.008 (Post-hoc superiority analysis: Wounds that were either evaluated controversially (n=2) or as being equal (n=2) were excluded from the analysis of the primary efficacy variable.)
SecondaryPercentage of Wound Epithelialization at Day 7±1

The secondary endpoint was the intra-individual difference in median percentage of wound epithelialization at Day 7±1. Sizes of wound areas were measured using a digital wound evaluation program from the EB Center at the Department of Dermatology, University Medical Center Freiburg.

Time frame:
Day 7±1
Reported as:
Median · Percentage of wound epithelialization
Percentage of Wound Epithelialization at Day 7±1
Percentage of wound epithelializationOleogel-S10 and Non-adhesive Wound DressingNon-adhesive Wound Dressing Only
Percentage of Wound Epithelialization at Day 7±169.7 (17.3 to 90.4)57.4 (10.0 to 81.3)
Statistical analysis
  • Oleogel-S10 and Non-adhesive Wound Dressing · Wilcoxon (Mann-Whitney) · p = =0.21 (Post-hoc superiority analysis)
SecondaryPercentage of Wound Epithelialization at Day 14±1

The secondary endpoint was the intra-individual difference in median percentage of wound epithelialization at Day 14±1. Sizes of wound areas were measured using a digital wound evaluation program from the EB Center at the Department of Dermatology, University Medical Center Freiburg.

Time frame:
Day 14±1
Reported as:
Median · Percentage of wound epithelialization
Percentage of Wound Epithelialization at Day 14±1
Percentage of wound epithelializationOleogel-S10 and Non-adhesive Wound DressingNon-adhesive Wound Dressing Only
Percentage of Wound Epithelialization at Day 14±187.7 (2.7 to 100.0)79.2 (0.0 to 98.3)
Statistical analysis
  • Oleogel-S10 and Non-adhesive Wound Dressing · Wilcoxon (Mann-Whitney) · p = 0.33 (Post-hoc superiority analysis)

Adverse events

Collected over Adverse events were recorded from start of study treatment (Day 0) to completion of study treatment (Day 14/Day 28), i.e. for a period of up to 2 or 4 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population—0/10 (0%)6/10 (60%)
Most frequent other events
Most frequent other events
EventSafety Population
Wound area increased due to trauma/wound dressing changeSkin and subcutaneous tissue disorders5/10
Wound infectionSkin and subcutaneous tissue disorders1/10
Flu-like syndromeInfections and infestations1/10

Baseline characteristics

As 2 participants received 2 cycles of treatment each, 12 wounds were treated with study medication.

Age, Categorical
Age, Categorical(Participants)All Study Participants
<=18 years5
Between 18 and 65 years5
>=65 years0
Age, Continuous
Age, Continuous(years)All Study Participants
Median20 (6 to 48)
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female3
Male7
Region of Enrollment
Region of Enrollment(participants)All Study Participants
Germany10
08

Study locations

1 site
  • EB Center at the Department of Dermatology, University Medical Center
    Freiburg, 79104, Germany
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 6 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2010
First posted
Feb 11, 2011
Start
Nov 2010
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Jan 23, 2018
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01294241
Lead sponsor
Birken AG
Responsible party
Sponsor
First posted
Feb 11, 2011
Start date
Nov 2010
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Jan 23, 2018
Last update
Jan 23, 2018

Study contacts

Agnes Schwieger-Briel, MD
principal investigator · University Medical Center Freiburg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Episalvan · Birch triterpenes

Start the discussion